Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 2
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression f…
Non-small Cell Lung Cancer Stage IIICNon-small Cell Lung Cancer Stage IVNon Small Cell Lung Cancer+2 more
University of California, DavisNCT07250477
Phase 3
PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lun…
Non-small Cell CarcinomaNon-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Carcinoma
PfizerNCT07144280